On Friday, April 24, 2026, shares of NFL Biosciences (WKN: A3CTQ0; ISIN: FR0014003XT0) were trading at EUR 0.03 according to real-time data from Deutsche Börse’s Xetra trading system. This valuation reflects the company’s current market position as a clinical-stage biotechnology firm focused on developing innovative smoking cessation therapies.
The share price data comes directly from Deutsche Börse’s live trading platform, which shows NFL Biosciences EO -,03 shares with no bid or ask prices indicated at the time of reporting. Trading activity for the stock showed zero volume, with no price changes recorded from the previous trading session. This static pricing situation is consistent with the company’s status as a specialized biotech firm whose shares may experience limited trading frequency on public exchanges.
NFL Biosciences, founded in 2009 by Bruno Lafont who serves as both Chairman of the Board and Chief Executive Officer, has been advancing its lead drug candidate NFL-101 through clinical development. The company announced on April 15, 2026 that it strengthened its cash position by €2.6 million through bond financing subscribed by a group of European institutional investors. This financing move was highlighted in a press release where Bruno Lafont stated: “We would like to thank the investors for their confidence in our mission to develop innovative solutions for smoking cessation.”
The company’s clinical progress centers on its smoking cessation portfolio, which includes NFL-101 as its first-in-class drug candidate. In December 2025, NFL Biosciences reported obtaining complementary characterization results for NFL-101 and preparing a new patent application to protect its intellectual property. Earlier in April 2026, the company presented its 2025 annual results and provided updates on clinical progress driven by what it describes as a new paradigm in smoking cessation treatment approaches.
Looking at the company’s governance structure, Bruno Lafont brings extensive experience from his previous role as Innovation Director and later President at PCM, an international French industrial group, where he served from 1999 to 2009. His background includes an engineering degree in biochemistry from INSA Toulouse, a Master’s in management from EMLyon, and an Executive MBA from EPFL and HEC Lausanne. The board also includes Dr. Ignacio Faus, who joined the company in 2019 as an investor before moving to the management team in early 2021, bringing 27 years of experience from pharmaceutical companies including Bristol Myers Squibb and Ferrer.
As a biotechnology company operating in the specialized field of addiction therapeutics, NFL Biosciences does not participate in traditional sports leagues or competitions. The company’s name, which includes the acronym “NFL,” refers solely to its corporate identity and has no connection to the National Football League or any sports organization. This distinction is important for investors and analysts who might encounter the stock symbol while researching biotechnology investments.
The current EUR 0.03 share price represents the market’s valuation of NFL Biosciences as it continues to advance its clinical programs. For investors tracking the company’s progress, key milestones to monitor include upcoming clinical trial results, regulatory interactions with agencies such as the European Medicines Agency and the U.S. FDA, and any additional financing activities that may support further development of its smoking cessation therapies.
As of the reporting date of April 24, 2026, the next significant event for NFL Biosciences would be the continuation of its clinical development programs and potential updates on its financial position. Investors interested in the company’s progress should refer to official company announcements and regulatory filings for the most accurate and timely information regarding its therapeutic developments and financial status.
